{'fraction_non_alphanumeric': 0.03282626100880705, 'fraction_numerical': 0.024819855884707767, 'mean_word_length': 4.681818181818182, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Clinical significance of tumor associated antigen TA-4 in gynecologic tumors].

Serum levels of TA-4, a tumor associated antigen of cervical squamous cell carcinoma, were measured in various gynecologic tumors with a RIA kit (DAINABOT). Immunohistochemical localization of TA-4 was also evaluated in the squamous cell carcinoma of the cervix. Serum TA-4 levels were elevated in 8.3% of patients with CIS, in 25% with stage Ia, in 56% with stage Ib, in 83% with stage II, in 75% with stage III and IV and in 100% with recurrent squamous cell carcinoma of the cervix, respectively. No patients were positive for TA-4 in endometrial and ovarian cancers. Serum TA-4 levels declined distinctively after treatment in accordance with the disappearance of initial tumors in some patients with advanced carcinoma. TA-4 was demonstrated immunohistochemically in 2 out of 8 CIS, 3 out of 8 microinvasive carcinoma, 4 out of 4 keratinizing type, 7 out of 7 large cell type and 3 out of 6 small cell type of invasive squamous cell carcinoma, respectively. In each type of carcinoma, TA-4 was positive in the differentiated cells. Similarly, it was found in the differentiated layers of normal squamous epithelium excluding the immature cells of the basal layer.